Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | TYMS | P04818 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 2/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA4 | P22748 | 2/20 | 0.30 |
| ▸ | CA5A | P35218 | 2/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL27596260 | 0.95 | SLC34A1 (0.67) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL28045127 | 0.95 | SLC34A1 (0.67) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL28146677 | 0.95 | SLC34A1 (0.67) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL21990207 | 0.95 | — | — | |
| Phosphoric Acid SCHEMBL2127340 | 0.90 | SLC34A1 (0.73) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL30904476 | 0.90 | SLC34A1 (0.73) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL2954685 | 0.90 | SLC34A1 (0.90) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL6926626 | 0.90 | SLC34A1 (0.73) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL34463363 | 0.90 | SLC34A1 (0.73) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL9901846 | 0.90 | SLC34A1 (0.73) | SLC34A1LMNAKDM4ECYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220273673-A1 | BONE-BINDING COMPOUNDS | BRIGHAM YOUNG UNIVERSITY (US) | 2022-09-01 | — | — | US | disclosed |
| CN-114585316-A | Osseointegrating compounds | 布莱阿姆青年大学 | 2022-06-03 | — | — | CN | disclosed |
| EP-4003201-A1 | BONE-BINDING COMPOUNDS | Brigham Young University (US) | 2022-06-01 | — | — | EP | disclosed |
| WO-2021016583-A1 | BONE-BINDING COMPOUNDS | BRIGHAM YOUNG UNIVERSITY (US) | 2021-01-28 | — | — | WO | disclosed |
| CN-105296024-B | A kind of multifunctional diesel oil cetane number improver and preparation method thereof | 广昌达新材料技术服务（深圳）股份有限公司 | 2017-08-29 | — | — | CN | disclosed |
| CN-105296024-A | Multifunctional diesel oil cetane number improver and preparation method thereof | SHENZHEN CESTO CHEMICAL COMPANY LED | 2016-02-03 | — | — | CN | disclosed |
| US-20110256065-A1 | Non-Isotopic Detection of Osteoblastic Activity In Vivo Using Modified Bisphosphonates | FRANGIONI JOHN V | 2011-10-20 | — | — | US | disclosed |
| US-20090123383-A1 | Non-Isotopic Detection of Osteoblastic Activity In Vivo Using Modified Bisphosphonates | BETH ISRAEL DEACONESS MEDICAL CENTER | 2009-05-14 | — | — | US | disclosed |
| US-7374746-B2 | Non-isotopic detection of osteoblastic activity in vivo using modified bisphosphonates | BETH ISRAEL DEACONEES MEDICAL CENTER (US) | 2008-05-20 | — | — | US | disclosed |
| CN-101098960-A | X-ray structure of human fpps and use for selecting fpps binding compounds | NOVARTIS AG (CH) | 2008-01-02 | — | — | CN | disclosed |
| US-20070036724-A1 | diagnostic detection of diseases accompanied with an abnormality of calcium hydroxyapatite using in vivo imaging; contrast agent comprising a fluorescent moiety covalently linked to a bisphosphonate moiety such as, alendronate, clodronate, EB-1053, etidronate, ibandronate, incadronate, neridronate | FRANGIONI JOHN V | 2007-02-15 | — | — | US | disclosed |
| US-20060002857-A1 | Non-isotopic detection of osteoplastic activity in vivo using modified bisphosphonates | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2006-01-05 | — | — | US | disclosed |
| US-6869593-B2 | Non-isotopic detection of osteoblastic activity in vivo using modified bisphosphonates | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2005-03-22 | — | — | US | disclosed |
| US-20040028611-A1 | Non-isotopic detection of osteoblastic activity in vivo using modified bisphosphonates | BETH ISRAEL DEACONESS MEDICAL CENTER, OF THE ENTIRE INERST. | 2004-02-12 | — | — | US | disclosed |
| EP-1341557-A2 | NON-ISOTOPIC DETECTION OF OSTEOBLASTIC ACTIVITY IN VIVO USING MODIFIED BISPHOSPHONATES | Beth Israel Deaconess Medical Center (US) | 2003-09-10 | — | — | EP | disclosed |
| EP-1131100-B1 | THERAPEUTIC COMPOSITIONS FOR METABOLIC BONE DISORDERS OR BONE METASTASES COMPRISING A PHOTOSENSITIZER AND A BISPHOSPHONATE | LIGHT SCIENCES CORP (US) | 2003-03-12 | — | — | EP | disclosed |
| US-20030018371-A1 | Compositions and methods for the treatment of metabolic bone disorders and bone metastases | LIGHT SCIENCES CORPORATION | 2003-01-23 | — | — | US | disclosed |
| WO-2002038190-A2 | NON-ISOTOPIC DETECTION OF OSTEOBLASTIC ACTIVITY IN VIVO USING MODIFIED BISPHOSPHONATES | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040028611-A1 | Non-isotopic detection of osteoblastic activity in vivo using modified bisphosphonates | SOST, ACP3, PHPT1 | SLC34A1 34/4885LMNA 1951/4885KDM4E 3447/4885 |
| US-20110256065-A1 | Non-Isotopic Detection of Osteoblastic Activity In Vivo Using Modified Bisphosphonates | SOST, ACP3, PHPT1 | SLC34A1 34/4885LMNA 1951/4885KDM4E 3447/4885 |
| US-20070036724-A1 | diagnostic detection of diseases accompanied with an abnormality of calcium hydroxyapatite using in vivo imaging; contrast agent comprising a fluorescent moiety covalently linked to a bisphosphonate moiety such as, alendronate, clodronate, EB-1053, etidronate, ibandronate, incadronate, neridronate | HCAR3, ENTPD3, SLC9A3 | SLC34A1 26/4885LMNA 2330/4885KDM4E 4234/4885 |
| US-20060002857-A1 | Non-isotopic detection of osteoplastic activity in vivo using modified bisphosphonates | SOST, ACP3, ALPP | SLC34A1 47/4885LMNA 2226/4885KDM4E 3777/4885 |
| US-20220273673-A1 | BONE-BINDING COMPOUNDS | CCL5, BMP2, CLTB | SLC34A1 35/4885LMNA 1214/4885KDM4E 4206/4885 |
| US-20090123383-A1 | Non-Isotopic Detection of Osteoblastic Activity In Vivo Using Modified Bisphosphonates | SOST, ACP3, PHPT1 | SLC34A1 34/4885LMNA 1951/4885KDM4E 3447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.